{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-096177","form_type":"8-K","ticker":"FATE","cik":"0001434316","company_name":"FATE THERAPEUTICS INC","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.049063+00:00","generated_at":"2026-05-31T09:40:33.440026+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Fate Therapeutics Q2 2024: Cash $352M; FT819 SLE study adds Cy; FT522 first patient without conditioning","bullets":["Cash, equivalents & investments $352.0M; projected operating runway through YE26.","Revenue $6.8M (incl. $5M milestone from Ono); GAAP operating expenses $51.9M (R&D $34.6M, G&A $17.3M).","FT819 Phase 1 SLE study: first patient (lupus nephritis) dosed; protocol amended to include single-agent cyclophosphamide; no Grade≥3 AEs, no CRS/ICANS/GvHD.","FT825/ONO-8250 Phase 1 solid tumor study: three patients treated as monotherapy; combo dosing with mAb expected 3Q24.","FT522 Phase 1 BCL study: first patient treated without conditioning chemotherapy at 300M cells/dose; IND for autoimmune basket study planned 3Q24."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-096177","json":"https://secwatch.observer/filing/0000950170-24-096177.json","markdown":"https://secwatch.observer/filing/0000950170-24-096177.md","text":"https://secwatch.observer/filing/0000950170-24-096177.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434316/000095017024096177/0000950170-24-096177-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434316/000095017024096177/fate-20240813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:40:33.440026+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}